Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Postmarketing Observational Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China

NCT03236870 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03236870
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03236870 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Postmarketing Observational Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
September 8, 2017
Completion date
August 25, 2020
Enrollment
181 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis